MCID: CHL128
MIFTS: 53

Childhood Hepatocellular Carcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Childhood Hepatocellular Carcinoma

MalaCards integrated aliases for Childhood Hepatocellular Carcinoma:

Name: Childhood Hepatocellular Carcinoma 11 19 14 71
Pediatric Hepatocellular Carcinoma 11 19 58 28 5
Childhood-Onset Hepatocellular Carcinoma 58
Childhood Carcinoma of Liver Cell 19
Pediatric Carcinoma of Liver Cell 19
Childhood Liver Cell Carcinoma 19
Pediatric Liver Cell Carcinoma 19
Childhood Liver Cancer 71
Childhood-Onset Hcc 58
Childhood Hepatoma 19
Pediatric Hepatoma 19
Pediatric Hcc 58

Characteristics:


Prevelance:

Pediatric Hepatocellular Carcinoma: 1-9/1000000 (Europe) <1/1000000 (United States) 58

Age Of Onset:

Pediatric Hepatocellular Carcinoma: Adolescent,Childhood 58

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 11 DOID:0070322
NCIt 49 C7955
ICD10 via Orphanet 32 C22.0
Orphanet 58 ORPHA33402
UMLS 71 C0279606 C2945767

Summaries for Childhood Hepatocellular Carcinoma

GARD: 19 Childhood hepatocellular carcinoma (childhood HCC) is a rare type of malignant (cancerous) tumor that forms in the cells and tissues of the liver. Childhood HCC is usually found in older children and adolescents (10-14 years), but has been found in children younger than 5. Symptoms may include a mass in the abdomen, a swollen and painful abdomen, weight loss, poor appetite, yellowing of the skin and eyes (jaundice), vomiting, fever, itchy skin, and a decreased number of red blood cells (anemia). The cause of childhood HCC is not well understood; however, underlying disorders that cause liver dysfunction (ex. hepatitis B) and congenital or genetic disorders that affect the liver (ex. tyrosinemia type 1) may increase the risk for childhood HCC to occur.

MalaCards based summary: Childhood Hepatocellular Carcinoma, also known as pediatric hepatocellular carcinoma, is related to fibrolamellar carcinoma and adult hepatocellular carcinoma, and has symptoms including fever, abdominal pain and icterus. An important gene associated with Childhood Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Signaling by Receptor Tyrosine Kinases and Hepatocyte growth factor receptor signaling. The drugs Amifostine and Sorafenib have been mentioned in the context of this disorder. Affiliated tissues include liver, skin and thyroid, and related phenotypes are hepatomegaly and hepatic fibrosis

Orphanet: 58 A rare, aggressive and malignant hepatic tumor arising from the hepatocytes. It develops mainly in children over 10 years of age, either in a cirrhotic background, or more commonly in a non-cirrhotic background (70% of cases).

Disease Ontology: 11 A hepatocellular carcinoma that occurs in children and is characterized by a distinct etiological predisposition, biological behavior, and lower frequency of cirrhosis as compared to adult hepatocellular carcinoma.

Related Diseases for Childhood Hepatocellular Carcinoma

Diseases related to Childhood Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
# Related Disease Score Top Affiliating Genes
1 fibrolamellar carcinoma 30.3 LINC01307 CTNNB1 AFP
2 adult hepatocellular carcinoma 30.2 SELENOI CTNNB1 AFP
3 hepatoblastoma 29.9 SLC22A18 MET HGF CTNNB1 AFP
4 cholangiocarcinoma 29.8 MET HGF CTNNB1 AFP
5 liver lipoma 10.2 CTNNB1 AFP
6 testicular fibroma 10.2 CTNNB1 AFP
7 hepatic coma 10.2 HGF AFP
8 hereditary renal cell carcinoma 10.2 MET HGF
9 pancreatoblastoma 10.2 CTNNB1 AFP
10 occipital lobe neoplasm 10.1 TPR MET
11 gastroesophageal adenocarcinoma 10.1 MET HGF
12 hepatitis b 10.1
13 viral hepatitis 10.1
14 liver benign neoplasm 10.1 CTNNB1 AFP
15 gummatous syphilis 10.1 TPR AFP
16 sarcoma, synovial 10.1 MET HGF CTNNB1
17 mesothelioma, malignant 10.0 MET HGF CTNNB1
18 familial renal papillary carcinoma 10.0 TPR MET HGF
19 viral infectious disease 10.0
20 tyrosinemia, type i 10.0
21 rare tumor 10.0
22 gastric adenocarcinoma 9.9 MET CTNNB1 AFP
23 acinar cell carcinoma 9.9 CTNNB1 AFP
24 hepatocellular carcinoma 9.9
25 biliary atresia 9.9
26 hemangioma 9.9
27 liver cirrhosis 9.9
28 tyrosinemia 9.9
29 49, xxxxy syndrome 9.9
30 alagille syndrome 1 9.9
31 cholestasis, progressive familial intrahepatic, 1 9.9
32 factor vii deficiency 9.9
33 alpha-thalassemia/mental retardation syndrome, x-linked 9.9
34 progressive familial intrahepatic cholestasis 9.9
35 non-alcoholic fatty liver disease 9.9
36 cholestasis 9.9
37 intrahepatic cholestasis 9.9
38 bilirubin metabolic disorder 9.9
39 glycogen storage disease 9.9
40 severe combined immunodeficiency 9.9
41 splenomegaly 9.9
42 cryptogenic cirrhosis 9.9
43 familial intrahepatic cholestasis 9.9
44 deafness, autosomal recessive 97 9.8 SEMA6A SEMA3B MET HGF
45 hepatitis 9.8
46 large congenital melanocytic nevus 9.7 HGF FCHSD1
47 renal cell carcinoma, papillary, 1 9.6 TPR SEMA6A SEMA3B MET HGF

Graphical network of the top 20 diseases related to Childhood Hepatocellular Carcinoma:



Diseases related to Childhood Hepatocellular Carcinoma

Symptoms & Phenotypes for Childhood Hepatocellular Carcinoma

Human phenotypes related to Childhood Hepatocellular Carcinoma:

58 30 (show all 9)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hepatomegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002240
2 hepatic fibrosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001395
3 abdominal pain 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002027
4 elevated alpha-fetoprotein 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0006254
5 vomiting 58 30 Frequent (33%) Frequent (79-30%)
HP:0002013
6 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
7 portal vein thrombosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0030242
8 epigastric pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0410019
9 hepatic necrosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0002605

UMLS symptoms related to Childhood Hepatocellular Carcinoma:


fever; abdominal pain; icterus; malaise

Drugs & Therapeutics for Childhood Hepatocellular Carcinoma

Drugs for Childhood Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
2
Sorafenib Approved, Investigational Phase 2, Phase 3 284461-73-0 216239
3
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
4
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
5
Irinotecan Approved, Investigational Phase 2, Phase 3 97682-44-5, 100286-90-6 60838
6
Vincristine Approved, Investigational Phase 2, Phase 3 2068-78-2, 57-22-7 5978
7
Picropodophyllin Approved, Investigational Phase 2, Phase 3 518-28-5, 477-47-4 10607 72435
8
Gemcitabine Approved Phase 2, Phase 3 95058-81-4, 122111-03-9 60750
9
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
10
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
11
Oxaliplatin Approved, Investigational Phase 2, Phase 3 61825-94-3 43805 11947679 6857599
12 Protective Agents Phase 3
13 Radiation-Protective Agents Phase 3
14 Anti-Bacterial Agents Phase 2, Phase 3
15 Antiviral Agents Phase 2, Phase 3
16
Etoposide phosphate Phase 2, Phase 3 16760419
17 Anti-Infective Agents Phase 2, Phase 3
18 Antimitotic Agents Phase 2, Phase 3
19 topoisomerase I inhibitors Phase 2, Phase 3
20 Keratolytic Agents Phase 2, Phase 3
21 Tubulin Modulators Phase 2, Phase 3
22 Antibiotics, Antitubercular Phase 2, Phase 3
23 Liposomal doxorubicin Phase 2, Phase 3
24 Dermatologic Agents Phase 2, Phase 3
25
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
26
Trametinib Approved Phase 2 871700-17-3 11707110
27
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
28
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
29
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
30
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
31 Vitamins Phase 2
32 Folate Phase 2
33 Vitamin B9 Phase 2
34 Hormones Phase 2
35 Trace Elements Phase 2
36 Vitamin B Complex Phase 2
37 Antidotes Phase 2
38 Calcium, Dietary Phase 2
39 Hematinics Phase 2
40 Micronutrients Phase 2
41 3-Iodobenzylguanidine Phase 2
42 Immunoglobulins Phase 2
43 Antibodies, Monoclonal Phase 2
44 Antibodies Phase 2
45 Antineoplastic Agents, Immunological Phase 2
46
Calcium Nutraceutical Phase 2 7440-70-2 271
47
Alvocidib Experimental, Investigational Phase 1 131740-09-5, 146426-40-6 5466794 5287969

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 Intergroup Protocol for Treatment of Children With Hepatoblastoma Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
2 Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) Recruiting NCT03533582 Phase 2, Phase 3 Carboplatin;Cisplatin;Doxorubicin;Etoposide;Fluorouracil;Gemcitabine;Irinotecan;Oxaliplatin;Sorafenib;Vincristine Sulfate
3 Phase III Randomized Study of Surgical Resection With Versus Without Postoperative Hepatic Arterial Chemotherapy in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus Withdrawn NCT00238160 Phase 3 cisplatin;fluorouracil
4 Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
5 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin
6 A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma Completed NCT01502410 Phase 2 sorafenib tosylate
7 A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC #742460) in Children With Relapsed/Refractory Solid Tumors Completed NCT00831844 Phase 2
8 The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study Recruiting NCT04134559 Phase 2 Pembrolizumab
9 A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 Imetelstat Sodium
10 A PHASE I STUDY OF FLAVOPIRIDOL (NSC# 649890; IND# 46211) IN PATIENTS WITH RELAPSED OR REFRACTORY PEDIATRIC SOLID TUMORS OR LYMPHOMAS Completed NCT00012181 Phase 1 alvocidib
11 Phase I Study of Doxorubicin HCl Liposome in Pediatric Patients With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
12 A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas Completed NCT00101270 Phase 1 irinotecan hydrochloride;oxaliplatin
13 Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC Completed NCT02072486 Sorafenib Tosylate
14 Genetics and Biology of Liver Tumorigenesis in Children Completed NCT01336881
15 Genetic and Molecular Basis of Pediatric Liver Cancer Recruiting NCT03959800

Search NIH Clinical Center for Childhood Hepatocellular Carcinoma

Genetic Tests for Childhood Hepatocellular Carcinoma

Genetic tests related to Childhood Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Pediatric Hepatocellular Carcinoma 28

Anatomical Context for Childhood Hepatocellular Carcinoma

Organs/tissues related to Childhood Hepatocellular Carcinoma:

MalaCards : Liver, Skin, Thyroid

Publications for Childhood Hepatocellular Carcinoma

Articles related to Childhood Hepatocellular Carcinoma:

(show top 50) (show all 93)
# Title Authors PMID Year
1
Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. 5
9927037 1999
2
Imaging Features of Hepatocellular Carcinoma in Children With and Without Underlying Risk Factors. 62
35544373 2022
3
Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study. 62
35561331 2022
4
Integrated analysis using ToppMiR uncovers altered miRNA- mRNA regulatory networks in pediatric hepatocellular carcinoma-A pilot study. 62
35859536 2022
5
Second Generation Small Molecule Inhibitors of Gankyrin for the Treatment of Pediatric Liver Cancer. 62
35804840 2022
6
Liver Transplantation for Pediatric Hepatocellular Carcinoma: A Systematic Review. 62
35267604 2022
7
Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study. 62
34060723 2021
8
Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma. 62
33769387 2021
9
C/EBPβ enhances efficacy of sorafenib in hepatoblastoma. 62
33945665 2021
10
Imaging and clinical features of pediatric hepatocellular carcinoma. 62
33751174 2021
11
Surgical management of pediatric hepatocellular carcinoma: An analysis of the National Cancer Database. 62
32660779 2021
12
Diagnostic Performance of LI-RADS Version 2018 for Evaluation of Pediatric Hepatocellular Carcinoma. 62
33620289 2021
13
Clinical, Pathological and Genetic Characteristics of Pediatric Hepatocellular Carcinoma Associated with Hepatitis B Virus Infection. 62
34007834 2021
14
Pediatric Hepatocellular Carcinoma. 62
32856229 2020
15
Pediatric Hepatoblastoma, Hepatocellular Carcinoma, and Other Hepatic Neoplasms: Consensus Imaging Recommendations from American College of Radiology Pediatric Liver Reporting and Data System (LI-RADS) Working Group. 62
32602829 2020
16
Sorafenib in pediatric hepatocellular carcinoma from a clinician perspective. 62
32183592 2020
17
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma. 62
32806748 2020
18
Clinical heterogeneity of pediatric hepatocellular carcinoma. 62
32307899 2020
19
Population-Based Analysis of Hepatocellular Carcinoma in Children: Identifying Optimal Surgical Treatment. 62
32272204 2020
20
Downregulation of SFRP1 is a protumorigenic event in hepatoblastoma and correlates with beta-catenin mutations. 62
32189106 2020
21
Hepatoblastoma and Pediatric Hepatocellular Carcinoma: An Update. 62
31554479 2020
22
Hepatitis B Virus Seropositivity Is a Poor Prognostic Factor of Pediatric Hepatocellular Carcinoma: a Population-Based Study in Hong Kong and Singapore. 62
33330043 2020
23
Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activation. 62
30977242 2019
24
Predisposing Conditions to Pediatric Hepatocellular Carcinoma and Association With Outcomes: Single-center Experience. 62
30676520 2019
25
Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. 62
30259629 2019
26
Surgical management of children and adolescents with upfront completely resected hepatocellular carcinoma. 62
29968976 2018
27
Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. 62
30648040 2018
28
Pediatric hepatocellular carcinoma. 62
30254403 2018
29
2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). 62
29427028 2018
30
Role of interventional radiology in managing pediatric liver tumors : Part 2: percutaneous interventions. 62
29396792 2018
31
Hepatocellular carcinoma in children: hepatic resection and liver transplantation. 62
30363724 2018
32
Management of pediatric hepatocellular carcinoma: A multimodal approach. 62
28631359 2017
33
Stereotactic body radiotherapy for pediatric hepatocellular carcinoma with central biliary obstruction. 62
28436210 2017
34
Pediatric hepatocellular carcinoma: challenges and solutions. 62
28144610 2017
35
Pediatric hepatocellular carcinoma in a developing country: Is the etiology changing? 62
27392999 2016
36
Cause and effect: the etiology of pediatric hepatocellular carcinoma and the role for liver transplantation. 62
27726261 2016
37
YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma. 62
27605415 2016
38
Hepatocellular Carcinoma in Children: Does Modified Platinum- and Doxorubicin-Based Chemotherapy Increase Tumor Resectability and Change Outcome? Lessons Learned From the SIOPEL 2 and 3 Studies. 62
26811523 2016
39
Distinct set of chromosomal aberrations in childhood hepatocellular carcinoma is correlated to hepatitis B virus infection. 62
26837720 2016
40
Effects of curcumin in pediatric epithelial liver tumors: inhibition of tumor growth and alpha-fetoprotein in vitro and in vivo involving the NFkappaB- and the beta-catenin pathways. 62
26515460 2015
41
Comparative Analysis and Functional Characterization of HC-AFW1 Hepatocarcinoma Cells: Cytochrome P450 Expression and Induction by Nuclear Receptor Agonists. 62
26310804 2015
42
Transarterial embolization for pediatric hepatocellular carcinoma with cardiac cirrhosis. 62
26013052 2015
43
Secular trends were considered in the evaluation of universal hepatitis B vaccination in Taiwan. 62
25660961 2015
44
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma. 62
25447203 2015
45
Hepatocellular Carcinoma in the Pediatric Population: A Population Based Clinical Outcomes Study Involving 257 Patients from the Surveillance, Epidemiology, and End Result (SEER) Database (1973-2011). 62
26663981 2015
46
Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. 62
24138022 2014
47
Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. 62
24210185 2013
48
Approach to pediatric hepatocellular carcinoma. 62
30992867 2013
49
Clinical characteristics and outcome of hepatocellular carcinoma in children and adolescents. 62
23794023 2013
50
Radioembolisation for treatment of pediatric hepatocellular carcinoma. 62
23212597 2013

Variations for Childhood Hepatocellular Carcinoma

ClinVar genetic disease variations for Childhood Hepatocellular Carcinoma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MET NM_000245.4(MET):c.3731A>G (p.Lys1244Arg) SNV Pathogenic
13890 rs121913677 GRCh37: 7:116423456-116423456
GRCh38: 7:116783402-116783402
2 MET NM_000245.4(MET):c.3750G>A (p.Met1250Ile) SNV Pathogenic
13889 rs121913676 GRCh37: 7:116423475-116423475
GRCh38: 7:116783421-116783421
3 MET NM_000245.4(MET):c.3518C>T (p.Thr1173Ile) SNV Pathogenic
13888 rs121913675 GRCh37: 7:116419007-116419007
GRCh38: 7:116778953-116778953

Cosmic variations for Childhood Hepatocellular Carcinoma:

8 (show top 50) (show all 15626)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM97724722 ZXDB liver,NS,carcinoma,hepatocellular carcinoma c.1308C>A p.D436E 23:57593356-57593356 20
2 COSM94430614 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 20
3 COSM94436083 ZSWIM1 liver,NS,carcinoma,hepatocellular carcinoma c.1399A>C p.S467R 20:45883991-45883991 20
4 COSM94063771 ZSCAN20 liver,NS,carcinoma,hepatocellular carcinoma c.2314G>T p.G772W 1:33494658-33494658 20
5 COSM88264637 ZRSR2 liver,NS,carcinoma,hepatocellular carcinoma c.304G>T p.E102* 23:15803788-15803788 20
6 COSM102741209 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 20
7 COSM131494492 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.1159A>G p.M387V 22:29049340-29049340 20
8 COSM103081572 ZNRF3 liver,NS,carcinoma,hepatocellular carcinoma c.859A>G p.M287V 22:29049340-29049340 20
9 COSM95977701 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 20
10 COSM102131817 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 20
11 COSM95960776 ZNFX1 liver,NS,carcinoma,hepatocellular carcinoma c.2580G>A p.L860= 20:49257501-49257501 20
12 COSM113317148 ZNF853 liver,NS,carcinoma,hepatocellular carcinoma c.1610G>T p.G537V 7:6622601-6622601 20
13 COSM99592496 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.829T>A p.F277I 19:36891962-36891962 20
14 COSM128686611 ZNF829 liver,NS,carcinoma,hepatocellular carcinoma c.1072T>A p.F358I 19:36891962-36891962 20
15 COSM123358576 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.691C>T p.L231= 4:145885684-145885684 20
16 COSM123949383 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 20
17 COSM101741672 ZNF827 liver,NS,carcinoma,hepatocellular carcinoma c.1741C>T p.L581= 4:145885684-145885684 20
18 COSM86004822 ZNF653 liver,NS,carcinoma,hepatocellular carcinoma c.1553A>C p.H518P 19:11485673-11485673 20
19 COSM98561269 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
20 COSM142353152 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
21 COSM142221290 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
22 COSM99854658 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.156G>A p.V52= 19:52002156-52002156 20
23 COSM139729931 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
24 COSM141470046 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
25 COSM141819438 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
26 COSM145038099 ZNF615 liver,NS,carcinoma,hepatocellular carcinoma c.141G>A p.V47= 19:52002156-52002156 20
27 COSM91868668 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.3900G>T p.K1300N 19:30557161-30557161 20
28 COSM91880764 ZNF536 liver,NS,carcinoma,hepatocellular carcinoma c.2171-78T>G p.? 19:30534769-30534769 20
29 COSM140721836 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.2998+205G>A p.? 18:25194955-25194955 20
30 COSM131506983 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 20
31 COSM94799980 ZNF521 liver,NS,carcinoma,hepatocellular carcinoma c.3658+205G>A p.? 18:25194955-25194955 20
32 COSM90582798 ZNF518B liver,NS,carcinoma,hepatocellular carcinoma c.1624G>T p.E542* 4:10444705-10444705 20
33 COSM87577038 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.6715G>T p.V2239L 9:106974156-106974156 20
34 COSM109096265 ZNF462 liver,NS,carcinoma,hepatocellular carcinoma c.3433G>T p.V1145L 9:106974156-106974156 20
35 COSM104985080 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.298+23785G>T p.? 2:179745718-179745718 20
36 COSM104427909 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.20G>T p.S7I 2:179745718-179745718 20
37 COSM151538615 ZNF385B liver,NS,carcinoma,hepatocellular carcinoma c.253+23785G>T p.? 2:179745718-179745718 20
38 COSM127708351 ZNF345 liver,NS,carcinoma,hepatocellular carcinoma c.47-856A>T p.? 19:36891962-36891962 20
39 COSM135887725 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1168C>G p.L390V 16:89734008-89734008 20
40 COSM84511025 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1219C>G p.L407V 16:89734008-89734008 20
41 COSM111609487 ZNF276 liver,NS,carcinoma,hepatocellular carcinoma c.1444C>G p.L482V 16:89734008-89734008 20
42 COSM92353291 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.1010C>T p.T337I 12:133010889-133010889 20
43 COSM130415812 ZNF26 liver,NS,carcinoma,hepatocellular carcinoma c.950C>T p.T317I 12:133010889-133010889 20
44 COSM88697750 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 20
45 COSM95253159 ZNF217 liver,NS,carcinoma,hepatocellular carcinoma c.*194A>T p.? 20:53569094-53569094 20
46 COSM94505616 ZMYND12 liver,NS,carcinoma,hepatocellular carcinoma c.425-1G>T p.? 1:42440026-42440026 20
47 COSM89943752 ZMYM4 liver,NS,carcinoma,hepatocellular carcinoma c.86-8201G>T p.? 1:35350724-35350724 20
48 COSM101398456 ZIC2 liver,NS,carcinoma,hepatocellular carcinoma c.-18C>T p.? 13:99982047-99982047 20
49 COSM113521587 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 20
50 COSM94679661 ZGPAT liver,NS,carcinoma,hepatocellular carcinoma c.*197C>A p.? 20:63736116-63736116 20

Expression for Childhood Hepatocellular Carcinoma

Search GEO for disease gene expression data for Childhood Hepatocellular Carcinoma.

Pathways for Childhood Hepatocellular Carcinoma

Pathways related to Childhood Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1 12.52 CTNNB1 GAB1 HGF MET MUC20
2
Show member pathways
12.19 MET HGF GAB1 CTNNB1
3
Show member pathways
12.14 MUC20 MET HGF GAB1
4
Show member pathways
12 MET HGF GAB1
5 11.79 MET HGF CTNNB1
6 11.79 MET HGF AFP
7 11.76 MET HGF AFP
8
Show member pathways
11.37 MET HGF CTNNB1
9 11.23 MET HGF GAB1
10
Show member pathways
11.09 MET HGF GAB1
11 11.04 MET HGF
12 11 MET HGF
13 10.96 MET HGF CTNNB1
14 10.87 MUC20 MET HGF GAB1 CTNNB1
15 10.58 MET HGF CTNNB1

GO Terms for Childhood Hepatocellular Carcinoma

Biological processes related to Childhood Hepatocellular Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myoblast proliferation GO:0051450 9.56 HGF CTNNB1
2 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.46 MET HGF
3 semaphorin-plexin signaling pathway GO:0071526 9.43 SEMA6A SEMA3B MET
4 hepatocyte growth factor receptor signaling pathway GO:0048012 9.1 MUC20 MET HGF

Sources for Childhood Hepatocellular Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....